Polygraphic evaluation of ethchlorvynol (14 days).
Ethchlorvynol 500 mg was administered to four young insomniacs for 14 days as part of a standard 22-day sleep laboratory protocol. Subjects slept more while receiving drug, but these benefits were not statistically significant. Ethchlorvynol impaired mood during both drug and withdrawal periods as compared to baseline, and serious side effects were reported. Stage REM and stage 1 were suppressed by ethchlorvynol, and stage 1 (but not stage REM) showed withdrawal rebound.
D000328:Adult; D001831:Body Temperature / Q000187:drug effects; D004644:Emotions / Q000187:drug effects; D004984:Ethchlorvynol / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D012894:Sleep Stages / Q000187:drug effects*; D013997:Time Factors
D004984:Ethchlorvynol